DCR-PHXC | Friends of Cancer Research

You are here

DCR-PHXC

Sponsor: 
Dicerna Pharmaceuticals
Indication: 
Primary hyperoxaluria type 1 (caused by a mutation in the AGXT gene)
Category: 
Year: 
2019
Date: 
Jul 15th
FDA Status: 
Designation Granted